Experimental cocktail aims to tackle tough blood cancers
NCT ID NCT06207123
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called LP-118 combined with three existing cancer medicines (ponatinib, vincristine, and dexamethasone) in adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to find a safe dose and see if the combination can put the cancer into remission. The trial is small, with 15 participants, and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LP-118 (experimental drug) combined with ponatinib, vincristine, and dexamethasone
What this could lead to
If successful, this could provide a new treatment option for people with hard-to-treat T-cell leukemia or lymphoma.
What could go wrong
This is an early-phase trial with only 15 participants, so results may not apply widely. The drug combination may cause serious side effects or fail to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60615, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Rochester Medical Center, Wilmot Cancer Center
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••